Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents
@article{Fong2007AntiobesityEO, title={Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-\{[5-(trifluoromethyl)pyridin-2-yl]oxy\}propanamide (MK-0364), in Rodents}, author={T. Fong and Xiao-ming Guan and D. Marsh and Chun-Pyn Shen and D. Stribling and Kim Rosko and Julie Lao and H. Yu and Y. Feng and J. Xiao and Lex H T van der Ploeg and M. Goulet and Williams K. Hagmann and Linus S. Lin and T. Lanza and James P. Jewell and P. Liu and S. Shah and Hongbo Qi and X. Tong and J. Wang and S. Xu and B. Francis and A. Strack and D. Macintyre and L. Shearman}, journal={Journal of Pharmacology and Experimental Therapeutics}, year={2007}, volume={321}, pages={1013 - 1022} }
The cannabinoid-1 receptor (CB1R) has been implicated in the control of energy balance. To explore the pharmacological utility of CB1R inhibition for the treatment of obesity, we evaluated the efficacy of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364) and determined the relationship between efficacy and brain CB1R occupancy in rodents. MK-0364 was shown to be a highly potent CB1R inverse agonist that… CONTINUE READING
Figures, Tables, and Topics from this paper
95 Citations
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
- Chemistry, Medicine
- Journal of medicinal chemistry
- 2010
- 13
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans
- Chemistry, Medicine
- Xenobiotica; the fate of foreign compounds in biological systems
- 2010
- 1
- Highly Influenced
In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys
- Chemistry, Medicine
- Xenobiotica; the fate of foreign compounds in biological systems
- 2010
- 5
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist
- Medicine, Chemistry
- BMC pharmacology
- 2010
- 11
Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
- Chemistry, Medicine
- European journal of pharmacology
- 2008
- 41
Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
- Chemistry, Medicine
- Future medicinal chemistry
- 2009
- 3
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
- Chemistry, Medicine
- Journal of medicinal chemistry
- 2008
- 34
- PDF
Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
- Biology, Medicine
- European journal of pharmacology
- 2010
- 14
Localisation of melanin-concentrating hormone receptor 1 in rat brain and evidence that sleep parameters are not altered despite high central receptor occupancy.
- Biology, Medicine
- European journal of pharmacology
- 2009
- 8
References
SHOWING 1-10 OF 46 REFERENCES
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
- Medicine
- Journal of medicinal chemistry
- 2006
- 37
Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
- Chemistry, Medicine
- Journal of medicinal chemistry
- 2004
- 147
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
- Biology, Medicine
- The Journal of clinical investigation
- 2005
- 967
- PDF
The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats
- Medicine, Biology
- Psychopharmacology
- 2005
- 49
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
- Chemistry, Medicine
- The Journal of pharmacology and experimental therapeutics
- 1992
- 193
Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding
- Medicine
- Pharmacology Biochemistry and Behavior
- 2000
- 139
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
- Medicine
- The Lancet
- 2005
- 1,238
- PDF
Observational analysis of feeding induced by Δ9-THC and anandamide
- Psychology
- Physiology & Behavior
- 2002
- 184
Observational analysis of feeding induced by Delta9-THC and anandamide.
- Medicine
- Physiology & behavior
- 2002
- 103